Panobinostat Potentiates Temozolomide Effects and Reverses Epithelial–Mesenchymal Transition in Glioblastoma Cells

摘要: Glioblastoma is the most common form of glioma, as well aggressive. Patients suffering from this disease have a very poor prognosis. Surgery, radiotherapy, and temozolomide are only approved treatments nowadays. Panobinostat pan-inhibitor histone deacetylases (HDACs) that has been shown to break some pathways which play an important role in cancer development. A global intention using panobinostat therapeutic agent against glioblastoma beginning be reality. We treated LN405 cell line with temozolomide, panobinostat, combined treatment, order test apoptosis, colony formation, possible molecular reversion mesenchymal phenotype cells epithelial one. Our results show decreased N-cadherin levels while it increased expression E-cadherin, might associated mesenchymal–epithelial transition cells. Colony formation was reduced, apoptosis treatments. research highlights importance potential adjuvant therapy used treat advantages treatment versus alone, currently first-line tumor.